• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Patent of Eli-Lilly's Blockbuster Lung Cancer Drug Alimta Upheld

Article

Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. patent for the drugmaker' s blockbuster lung-cancer drug, Alimta.

patent

Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. for the drugmaker' s blockbuster lung-cancer drug, Alimta.

s,

Teva Pharmaceutical Industries

he '209

Patent

a

The court said the defendantLtd, APP Pharmaceutical, now known as Fresenius Kabi USA LLC, Barr Laboratories Inc and Pliva Hrvatska D.O.O., failed to show by clear evidence that the asserted claims of tre invalid.

However, the decision that would preserve the $2.6 billion-a-year drug from generic competition until 2022, could change if generic drug companies appeal the ruling.

Read the complete report here:

http://reut.rs/1s2sdUK

Source: Reuters

Related Videos
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Screenshot of an interview with Shaun McKenzie, MD
Screenshot of an interview with Shaun McKenzie, MD
Screenshot of an interview with Rohan Garje, MD
Susan Escudier, MD, FACP
Sabarish Ayyappan, MD
Susan Escudier, MD, FACP
Screenshot of an interview with Evangelia Vlachou, MD
Screenshot of an interview with Barry Goy, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.